{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:04:27Z","timestamp":1791475467504,"version":"4.3.4"},"reference-count":69,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiology"],"published-print":{"date-parts":[[2024,5,2]]},"DOI":"10.2217\/fmb-2023-0248","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T14:24:28Z","timestamp":1709303068000},"page":"563-576","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":44,"title":["Sulbactam\u2013durlobactam: a \u03b2-lactam\/\u03b2-lactamase inhibitor combination targeting\n            <i>Acinetobacter baumannii<\/i>"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7827-794X","authenticated-orcid":false,"given":"Sarah M","family":"McLeod","sequence":"first","affiliation":[{"name":"Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5502-8738","authenticated-orcid":false,"given":"John P","family":"O'Donnell","sequence":"additional","affiliation":[{"name":"Innoviva Specialty Therapeutics, Inc., an affiliate of Entasis Therapeutics Inc., 35 Gatehouse Drive, Waltham, MA 02451, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5071-9193","authenticated-orcid":false,"given":"Navaneeth","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Rutgers University Ernest Mario School of Pharmacy, Department of Pharmacy Practice &amp; Administration, Piscataway, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-2911","authenticated-orcid":false,"given":"John P","family":"Mills","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology &amp; Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2051-1732","authenticated-orcid":false,"given":"Keith S","family":"Kaye","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology &amp; Infectious Diseases, Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,3]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"Centers for Disease Prevention and Control. Antibiotic Resistance Threats in the United States (2019). https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html (Accessed 14 January 2024)."},{"key":"e_1_3_5_4_1","unstructured":"European Centre for Disease Prevention and Control. Rapid Risk Assessment: Carbapenem-resistant Acinetobacter baumannii in Healthcare Settings (2016). https:\/\/www.ecdc.europa.eu\/en\/publications-data\/rapid-risk-assessment-carbapenem-resistant-Acinetobacter-baumannii-healthcare (Accessed 14 January 2024)."},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011520"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12363"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad100"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra070741"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad428"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics10111344"},{"key":"e_1_3_5_11_1","unstructured":"XACDURO\u00ae (sulbactam for injection; durlobactam for injection) co-packaged for intravenous use. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/216974Orig1s000Correctedlbl.pdf (Accessed 14 January 2024)."},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2013.07.012"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01612-17"},{"issue":"1","key":"e_1_3_5_14_1","first-page":"37","article-title":"Sulbactam: a \u03b2-lactamase inhibitor","volume":"7","author":"Noguchi JK","year":"1988","unstructured":"Noguchi JK, Gill MA. Sulbactam: a \u03b2-lactamase inhibitor. Clin. Pharm. 7(1), 37\u201351 (1988).","journal-title":"Clin. Pharm."},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt275"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2015.00231"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/nmicrobiol.2017.104"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad109"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00113"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.814530"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa208"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2021.05.001"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00781-22"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2022.05.011"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa119"},{"key":"e_1_3_5_27_1","unstructured":"FDA. Antimicrobial susceptibility test interpretive criteria. sulbactam\u2013durlobactam. https:\/\/www.fda.gov\/drugs\/development-resources\/sulbactam-and-durlobactam-injection (Accessed 14 January 2024)."},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01576-17"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02534-19"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00665-23"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00159-19"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.4.1432-1440.2005"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.7b00168"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.6.793"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/26.5.677"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.4.479"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.6.1406"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2014.02.012"},{"issue":"10","key":"e_1_3_5_39_1","first-page":"2296","article-title":"In vitro pharmacodynamics of human-simulated exposures of ampicillin\/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii","volume":"68","author":"Housman ST","year":"2013","unstructured":"Housman ST, Hagihara M, Nicolau DP, Kuti JL. In vitro pharmacodynamics of human-simulated exposures of ampicillin\/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 68(10), 2296\u20132304 (2013).","journal-title":"J. Antimicrob. Chemother."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02307-18"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad096"},{"key":"e_1_3_5_42_1","unstructured":"U.S. Food and Drug Administration. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/antibacterial-therapies-patients-unmet-medical-need-treatment-serious-bacterial-diseases"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00071-20"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01089-18"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12991"},{"issue":"9","key":"e_1_3_5_46_1","first-page":"e00794","article-title":"Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects","volume":"63","author":"O'Donnell J","year":"2019","unstructured":"O'Donnell J, Preston RA, Mamikonyan G, Stone E, Isaacs R. Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects. Antimicrob. Agents Chemother. 63(9), e00794\u201319 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01506-19"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00184-6"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1086\/599225"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00597-w"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30796-9"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30731-3"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00194-8"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.718"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.01600-22"},{"key":"e_1_3_5_56_1","unstructured":"XERAVA\u00ae (eravacycline) for injection for intravenous use. Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/211109lbl.pdf"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00436-16"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2023.04.017"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1029"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00479-22"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280221085551"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2019.0423"},{"issue":"4","key":"e_1_3_5_64_1","first-page":"1715","article-title":"Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative pathogens","volume":"11","author":"Morrisette T","year":"2022","unstructured":"Morrisette T, Alosaimy S, Lagnf AM et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant Gram-negative pathogens. Infect. Dis. Ther. 11(4), 1715\u20131723 (2022).","journal-title":"Infect. Dis. Ther."},{"key":"e_1_3_5_65_1","unstructured":"CLSI. Performance standards for antimicrobial susceptibility testing M100-S33(33rd ed.). CLSI PA USA (2023)."},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01268-16"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx368"},{"key":"e_1_3_5_68_1","first-page":"P2126","volume-title":"ECCMID.","author":"McLeod S","year":"2023","unstructured":"McLeod S, Carter N, Miller A. In vitro susceptibility of Acinetobacter baumannii-calcoaceticus complex (ABC) to sulbactam\u2013durlobactam in combination with a carbapenem. Presented at: ECCMID. Copenhagen, Denmark, P2126, 15\u201318 April 2023."},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353"},{"key":"e_1_3_5_70_1","unstructured":"VABOMERE\u00ae (meropenem and vaborbactam) for injection for intravenous use. Prescribing information."},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2011.03570.x"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2023-0248","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T05:20:03Z","timestamp":1727241603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2023-0248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":69,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,5,2]]}},"alternative-id":["10.2217\/fmb-2023-0248"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2023-0248","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}